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ABSTRACT 
Objective: The objective of the present study was to develop sustained release biodegradable polymeric nanoparticles of rosuvastatin calcium. 
Methods: Nanoparticles were prepared by modified ionotropic gelation method using 3² full factorial designs. From the preliminary trials, the 
constraints for independent variables X1 (concentration. of chitosan) and X2 (concentration. of sodium tripolyphosphate) have been fixed. Factors 
included concentration of chitosan and sodium tripolyphosphate, have been examined to investigate effect on particle size, encapsulation efficiency, 
zeta potential, % release, scanning electron microscopy, Fourier transfer infrared study and X-ray diffraction and release study of rosuvastatin 
calcium nanoparticles. 0 
Results: The prepared nanoparticles were white, free-flowing and spherical in shape. The infrared spectra showed stable character of rosuvastatin 
calcium in the drug-loaded nanoparticles and revealed the absence of drug polymer interactions. The chitosan nanoparticles have a particle 
diameter ranging approximately 114.5±3.61 to 724±.2.51 nm and a zeta potential-13.12 to-52.63 mV. The in vitro release behavior from all the drug 
loaded batches were found to follow first order and provided sustained release over a period of 10 h. The Zeta potential of all the batches were in 
the range of-13.12 to-52.63 mv. The release profiles of all batches were very well fitted by Korsmeyer Peppas model.  
Conclusion: The best-fit release kinetics was achieved with Korsmeyer peppas model. The release of rosuvastatin calcium was influenced by the 
drug to polymer ratio and particle size. These results indicate that rosuvastatin calcium nanoparticles could be effective in sustaining drug release 
for a prolonged period.  
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INTRODUCTION 
One of the most attractive areas of research in drug delivery today is 
the design of nanoparticulate systems that are able to deliver drugs 
to the right place, at appropriate times and at the right dosage. 
Nanoparticulate delivery systems, are unit the reduction of drug 
particle to the nano-scale, increases dissolution velocity and 
saturation solubility, have the potential power to improve drug 
stability, increase the duration of the therapeutic effect and permit 
administration through enteral or parenteral administration, which 
may prevent or reduces the drug degradation and metabolism as 
well as cellular efflux. Therapeutic efficacy of a drug mainly depends 
upon bioavailability and, ultimately upon the solubility of drug 
molecules. Solubility is one of the factors to attain the desired 
concentration of drug in systemic circulation for pharmacological 
response to be shown.  
Rosuvastatin calcium is the one of the most effective 
antihyperlipidemic drug and is termed "superstatin". It reduces the 
low-density lipoprotein-C (LDL-C) by 63% after an administration of 
40 mg dose [1, 2]. Rosuvastatin calcium is a poorly water-soluble 
drug with a low oral bioavailability i.e. 20%. It is classified by 
biopharmaceutical class II drug. It is a poorly water-soluble 3-
hydroxy-3-methyl glutaryl CoA reductase inhibitor. Due to this 
enzyme catalyzes the conversion of HMG-CoA to mevalonate, which 
is an early and rate-limiting step in cholesterol biosynthesis, a 
potent lipid lowering ingredient and used as a hyperlipidemic agent 
[3]. The poor solubility of Rosuvastatin calcium affects its 
dissolution rate and, in turn, its bioavailability. Thus, enhancing the 
dissolution of Rosuvastatin calcium can lead to improve its oral 
bioavailability. Accordingly, several nanosization approaches were 
adopted to improve Rosuvastatin calcium dissolution and 
bioavailability [4]. 
The conventional drug delivery system has been characterized by 
immediate drug release and repeated doses of the drug, which could 
result in the sudden of dose fluctuation [5]. The main aim of 
designing nanoparticles as a drug delivery system is very important 
particle size, surface properties and to deliver pharmacologically 
active agents at the right place, at the rational rate and dose [6, 7]. 
Therefore, it's important to introduce effective methods to boost the 
solubility and dissolution rate of the drug, substantially resulting in its 
enhanced oral bioavailability. Sustained-release formulations 
nanoparticles are reported to resolve these problems because of the 
alteration of its tissue distribution, improving the drug efficacy, 
reducing the drug toxicity, and prolonging the half-lives in blood [8, 9].  
Chitosan (CH) is a natural cationic polysaccharide consisting of (1-
4)-2-amino-2-deoxy-D-glucopyranosyl units. It breaks down are 
slowing the harmless products (amino sugars), which are completely 
absorbed by the human body [11, 12]. The degree of distillation and 
molecular weight are the two fundamental parameters that can 
affect the properties and functionality of chitosan. These properties 
include solubility, viscosity, reactivity of proteinaceous material 
coagulation, and heavy metal ion chelation and physical properties 
of films formulated using chitosan such as tensile strength, elasticity, 
elongation, and moisture absorption [10]. Chitosan has been used as 
a nanoparticle material owing to its versatile biodegradability, 
biocompatibility, a natural origin. Biodegradable nanoparticulate 
systems have received considerable attention as potential drug 
delivery vehicles [13].  
The objective of the present study was to evaluate the possibility of 
chitosan nanoparticles as carriers for Rosuvastatin calcium. The 
challenge was to entrap a hydrophobic molecule into hydrophilic 
nanoparticle formed by the process of ionotropic gelation technique 
based on the interaction between the negatively charged of the 
sodium tripolyphosphate (STPP) and the positively charged amino 
groups of chitosan. This ionotropic gelation process is due to the 
formation of inter and intra cross-linkages between/within polymer 
chains, mediated by the polyanions. The cationic nature of chitosan 
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has been conveniently exploited for the development of particulate 
drug delivery systems. More recently, chitosan NPs have been 
developed based on the ionotropic gelation of chitosan with sodium 
tripolyphosphate, for drug encapsulation [14]. 
MATERIALS AND METHODS 
Materials 
Rosuvastatin calcium was procured as gift sample from MSN 
Laboratories Pvt. Hyderabad. Sodium tripolyphosphate was 
purchased from Sigma-Aldrich, Mumbai; Chitosan (high viscosity) 
was purchased from Central Institute of Fisheries Cochin. All other 
reagents and chemicals used were of analytical grade. 
Experimental methods 
Preparation of chitosan nanoparticles 
Chitosan nanoparticles containing Rosuvastatin calcium were 
prepared by ionotropic gelation method. Chitosan was dissolved in 1 
% acetic acid solutions at various concentrations to obtain (0.1 %, 
0.2 % and 0.3 % i.e. 35 mg, 65 mg and 90 mg) and adjusted the pH 5-
6 with 0.1 N sodium hydroxide solutions, while sodium 
tripolyphosphate was dissolved in deionized water at various 
concentrations to obtain 0.1 %, 0.15 % and 0.20 % while stirring at 
750 rpm. Rosuvastatin calcium 50 mg was dissolved in 
ethanol/water mixture (1:1 v/v) (1 wt. % tween 80) to obtain clear 
solution. Rosuvastatin calcium solution was added dropwise during 
probe sonication with syringe needle size 0.45 mm to 40 ml chitosan 
solution. Repeat the sonication cycles for 1 h. The 20 ml of sodium 
tripolyphosphate solution was added dropwise 0.75 ml/min. under 
stirring (1000 rpm) at ambient temperature. The formulation was 
stirred for 30 min so as to remove ethanol content. All the 
formulations were sonicated at fixed time for 30 min. All experiments 
were performed in triplicates. Nanoparticles were collected by 
centrifugation at 9000 rpm for a period of 1 h and supernatant was 
analyzed using UV-Visible spectrophotometerically to determine 
encapsulation efficiency. Pellet was redissolved for sonicated for 15 
min. The sample was freeze-dried at-40 °C and lyophilized to get dry 
powder using 2 % Mannitol as cryoprotectant [15-17]. 
Freeze-drying of nanoparticles  
Briefly, by taking 5 ml of nanoparticles, dispersion was filled in 10 
ml glass vials, covered with special stoppers for lyophilization and 
placed in a freeze dryer (Southern scientific lab Instrument, India) 
After freeze-drying all sample vials were stored at 2-8 °C.  
Experimental design 
Full factorial design Optimization of rosuvastatin calcium loaded 
nanoparticles was done by using 32 factorial designs. In this design, 
amount of chitosan (CH) (X1) and amount of STPP (X2) were 
evaluated as independent variables. Formulated 9 possible 
combinations using 32 factorial design by taking each independent 
variable at 3 different levels as shown in table 1. Evaluated fixed 
responses particles size and % cumulative drug release as Y1 and 
Y2, respectively. 
The formulations batches were designed according to a 3² full 
factorial, allowing the simultaneous evaluation of two formulation 
variables and their interaction. 
  
Table 1: Parameters for 3² full factorial design batches code and experimental design 
 
Batches  









(ml) Drug: polymer ratios (X2) STPP (X2) 
RF1 2 2 65 30 200 750 1.5 
RF2 3 1 90 20 200 750 1.5 
RF3 3 2 90 30 200 750 1.5 
RF4 1 2 35 30 200 750 1.5 
RF5 1 1 35 20 200 750 1.5 
RF6 1 3 35 40 200 750 1.5 
RF7 2 3 65 40 200 750 1.5 
RF8 2 1 65 20 200 750 1.5 
RF9 3 3 90 40 200 750 1.5 
 
Table 2: Coded levels to actual quantities translation 
Coded levels +1 0 -1 
Drug: Polymer ratios (X1) in mg 1:3 (90) 1:2 (65) 1:1 (35) 
Sodium tripolyphosphate (X2) in % 0.2 0.15 0.1 
 
Characterization of rosuvastatin calcium nanoparticles  
Determination of particle size and polydispersity index 
The size distribution and polydispersity index (PDI) of the 
formulations were measured by Dynamic Light Scattering Particle 
Size Analyzer (Nanoplus 3, Micromeritics USA). The average 
diameter and a measure of the distribution width (polydispersity) 
were determined from the particle size distribution data. 
Polydispersity index varies from 0.0 to 1.0. The usual range of PDI 
values: 0-0.05 (monodisperse standard). 
X-ray diffraction (XRD) analysis 
XRD patterns were obtained at room temperature using a very high-
resolution Cu-Kα radiation diffraction system (Bruker D8 Advance 
diffractometer). The instrument was equipped with high-speed 
dispersive LYNXEYE XE-T detector and monochromatic Kβ radiation 
the sample was scanned over 2θ of 3-50° [18]. 
Fourier transforms infrared spectroscopy (FTIR) 
Infrared spectroscopy analysis was carried out to see the chemical 
composition of the prepared nanoparticles using FTIR (Nicolet, USA) 
operating within the frequency range of 400–4000 cm-1 at the 
absorption mode. 
Scanning electron microscopy (SEM) 
The prepared microspheres were coated with a thin layer of gold by 
sputtering (Hitachi High E-1010, Japan) and so the microstructure 
was observed in a scanning microscope (SEM; Hitachi High S-4800, 
Japan) that operated at an acceleration voltage of 20 kV.  
Determinations of drug content 
A quantity of rosuvastatin calcium drug-loaded nanoparticles equivalent 
to 1 mg was added to 10 ml methanol and phosphate buffer pH 7.4 
(1:10) mixtures and stirred continuously for 2 h and so the ultimate 
colloidal suspensions were ultracentrifuged at 10000 rpm for half an 
hour. The supernatant was analyzed for drug content by measuring the 
absorbance at 240 nm using UV spectrophotometer [19].  
Entrapment efficiency 
The Entrapment efficiency of nanoparticles was determined by the 
separation of drug-loaded Nanoparticles from the aqueous medium 
containing non-associated rosuvastatin calcium by 
ultracentrifugation at 12,000 rpm at 4 °C for 1 hr. the quantity of 
rosuvastatin calcium loaded into the nanoparticles was calculated as 
the difference between the total amount used to prepare the 
nanoparticles and also the amount that was found within the 
supernatant. The quantity of free rosuvastatin calcium within the 
supernatant was measured by UV Spectrophotometer [20, 21]. 
Entrapment efficiency was then calculated as follow
efficiency was calculated by Eq.1 
Percentage yield 
Fixed volumes of Rosuvastatin calcium nanosuspension were 
centrifuged at 9000 rpm for 30 min at 15 °C. The obtained sediment 
was dried and weighed [20]. The percentage yield was calculated by 
Eq.2 
Zeta potential 
The zeta potential value of optimized Rosuvastatin calcium loaded 
chitosan nanoparticle formulation was measured with the 
To determine the zeta potential, optimized formulation was diluted 
with double-distilled water and placed in an electrophoretic cell 
[22]. 
In vitro drug release 
The release of Rosuvastatin calcium from nanoparticles was 
evaluated using USP type II paddle apparatus over 24 hr
membrane was loaded with nanoparticle formulation containing 10 
mg equivalent of the drug, which was suspended initially for 
900 ml of 0.1N HCl buffer of pH 7.4 phosphate buffer upto 10 hr 
maintained at 37±0.5 °C and 50 rpm. At regular intervals
1 ml of the sample were withdrawn and replaced with the identical 
volume of the respected fresh buffer solution. The amount of 
released drug was assessed by UV-1700 analysis at 240 nm 
(Shimadzu UV-1700, Japan) after dilution. 
Kinetic modelling 
To study the release kinetics from NPs loaded rosuvastatin calcium, 
the release data of the optimized formulation RF4 nanoparticle 
batch were fitted to Zero order (Eq. (1), First-order (Eq.
(Eq. (3) and Korsemeyer-Peppas (Eq. (4). These kinetic modelling 
were analyzed by using Microsoft Office Excel (2013) to obtain the 
best fit model for the in vitro release [21]. 
Qt = Q0+K0t ………. (1) 
Log C = log C0 − Kt/2.303 …… 
ʄ = t1/4 KH t1/2 …… (3) 
ʄt = atn …… (4) 
Table 3: Average particle size, PDI, % product yield and % 










*Data expressed as (mean±SD (N=3)) 
 
Bhokare et al. 






2 h in 
, aliquots of 
 (2), Higuchi 
(2) 
Statistical analysis  
Statistical analysis was performed for different formulae by applying 
factorial design using DOE by Minitab 17. The effect of the polymer 
and particle size of different formulations on the percent cumulative 
drug release was found out to optimize the best formulation for 
further studies. 3D surface plots and contour plots were drawn for 
supporting the selected ratios and selected formulations.
Stability studies 
Stability studies were performed for polymeric nanoparticles to 
investigate the loss of drug from nanoparticle and change in 
nanoparticle structure during storage condition. Optimized 
formulation RF4 nanoparticles were subjected to accelerated 
stability studies as per ICH guidelines (
30±2 °C/65±5% RH) for a period of 
observed for particle size, % entrapment efficiency and drug release 
were carried out at every one-month interval [22].
RESULTS AND DISCUSSION 
Particle size and Size distribution
The mean particle size for formulations RF1 to RF9 varied in range 
of 114±0.16 to 724±2.51 (table 
particle size increases with the increase in the polymer 
concentration upto a level. The mean polydispersity index values for 
the rosuvastatin calcium loaded chitosan nanoparticle formulations 
RF1 to RF9 are in the range of 0.341
results of PDI can be simultaneously checked with particle size 
analysis. A monodisperse sample indicates PI value nearer to
However, PDI<1 indicates polydisperse samples. Therefore, PI 
determination was essential to confirm the size distribution of the 
particles [14]. 
 
Fig. 1: Particle size analysis of formulation RF4 
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Powder X-ray diffraction (PXRD) studies 
Drug crystallanity peaks were also detectable in the formulation. 
Compared with the PXRD patterns of pure rosuvastatin calcium and 
other formulation, the PXRD patterns of pure drug rosuvastatin 
calcium has the highest peak (2946) at 2θ range of 24.7, other peaks 
were (2385) at 2θ range of 20.1, (2294) at 2θ range of 1808, (2094) 
at 2θ range of 17.9, (1869) at 2θ range of 16.9 and (1599) at 2θ 
range of 15.9. While RF4 batch formulation has the highest peak 
(2825) at 2θ range of 9.47, other peaks were (7510) at 2θ range of 
13.69, (21329) at 2θ range of 17.28, (10610) at 2θ range of 20.41, 
(14607) at 2θ range of 21.37,(4157) at 2θ range of 23.42, (3470) at 
2θ range of 27.5, (3216) at 2θ range of 34.0, and (2006) at 2θ range 
of 43.8 indicating the amorphous nature of the drug in the 
formulation. These results confirm that rosuvastatin calcium is 
present as a crystalline material. The overlain spectra of 
rosuvastatin calcium and RF4 batch were shown in fig. 2. 
FTIR analysis 
The samples that were analyzed by FTIR were plain drug samples, 
physical mixture of drug and chitosan (1:1) and nanoparticulate 
formulation (Batch RF4). The IR spectrum of RC exhibited 
characteristic peaks at 3367.71 cm-1 (carboxylic OH stretch), 
2968.45 cm-1 (N-H stretch), 1543.05 cm-1 (C=C stretch), 1435.04 
cm-1 and 1377.17 cm-1 (asymmetric and symmetric vibrations of 
CH3), 1149.57 cm-1 (C-F stretch) and 514.99 cm-1, 596.0 cm-1, 
(absorption bands of out of plane C=C of benzene ring). These peaks 
were retained in the overlain IR spectra of both the physical mixture 
of RC and polymer and in the IR spectrum of optimized formulation 
(fig. 3). These observations confirm the compatibility between drug 
and excipients and lack of any chemical interactions. 
 
 




Fig. 3: Overlain FTIR spectra of chitosan (red), rosuvastatin (black), physical mixture (green) and NPs batch (blue) 
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Scanning electron microscopy study 
The exhibited from the SEM of Rosuvastatin calcium pure drug 
consisted of a mixture of large crystals, indicating its crystalline nature. 
However, the prepared Rosuvastatin calcium-loaded chitosan NP’s of 
batch RF4 had a spherical shape with relatively uniform size and no 
drug crystals were present, which was shown in SEM of pure 
Rosuvastatin calcium. The SEM of pure Rosuvastatin calcium (A), RF4 
batches (B) were nearly spherical in shape depicted in fig. 4. 
Drug content study 
Drug content varies in the range of 61.49±0.28 to 86.05±0.85 % and 
was determined using the UV spectroscopic analysis at 240 nm. Drug 
content of optimized RF4 batch was found to be 65.87±0.356 %. Low 
loss of drug content of all formulation batches during freeze-drying 
resulted in good recovery. 
Entrapment efficiency 
The encapsulation efficiency of the nanoparticles was found to vary 
between 78.6±0.21-98.5±0.30, which shown in table 4. Formulation 
RF4 shows 98.5±0.035 maximum entrapment efficiency. Based on 
entrapment efficiency and drug content formulation RF4 was taken 
as an optimized formulation [19, 20]. The entrapment efficiency not 
only depends on the chitosan concentration but also depends on the 
concentration of the surfactant used. 
  
Table 4: %drug entrapment efficacy and zeta potential of nanoparticles (mean±SD; n=3) 
Formulation batches % drug entrapment ±SD* Zeta potential±SD* 
RF1 98.0±0.25 -52.63±0.30 
RF2 94.3±0.10 -35.53±0.36 
RF3 78.6±0.21 -42.6±0.31 
RF4 98.5±0.30 -45.11±0.15 
RF5 96.7±0.15 -44.56±0.56 
RF6 84.3±0.41 -49.64±0.10 
RF7 81.4±0.20 -29.14±0.20 
RF8 94.2±0.34 -24.22±0.25 
RF9 93.6±0.38 -13.12±0.10 
*Data expressed as (mean±SD (N=3)) 
 
 
Fig. 5: Zeta potential of optimized formulation (RF4 batch) 
 
Percentage yield 
Percentage yield was found to be 39±0.605 % to 54±0.860 % for 
formulation RF1 to RF9 (table 3). Percentage practical yield depends 
on the concentration of polymer added, as the concentration of 
polymer increases, there is increases in the % yield. % yield 
obtained is 53.8±0.734% for formulation RF4 batch. 
Zeta potential 
Zeta Potential of the formulations was found, ranging from-
13.12±0.010to-52.63±0.030 (table 4). Zeta potential indicates the 
stability of the dispersed particles in the dispersion medium. High zeta 
potential shows high repulsion between the particles and particle 
aggregation is less likely to occur. A negative value of the zeta potential 
shows that formulations have good stability and dispersion quality [20]. 
In vitro drug release 
In vitro drug release studies were carried out using USP Type II 
dissolution apparatus (EDT.08LX, 1292092, Elestro Lab, India), at 
rotation speed of 50 rpm. The cumulative percentage drug release of 
Rosuvastatin calcium in Phosphate buffer pH 7.4 medium of RF1 to 
RF9 batches were shown in fig. 6. Cumulative percentage drug 
released for RF1, RF2, RF3, RF4, RF5, RF6, RF7, RF8, and RF9 after 
10 h were found to be 99.50%, 80.55% 79.97%, 88.49%,80.39%, 
89.41%,86.12%,90.02% and 90.73% respectively. It was apparent 
that in vitro release of Rosuvastatin calcium showed a very rapid 
initial burst and then followed by a very slow drug release. 
Evaluation of the release profiles of pure drug showed that almost 
all the Rosuvastatin calcium was released immediately during first 3 
h it has reached 36.51±0.02%, suggesting that the developed 
nanoparticles can be used as an important platform for sustained 
drug release which is shown in fig. 7, which would contribute to 
lower dosing frequency. Finally, it can be concluded that the 
different drug release rates may be attributed to different sizes of 
the nanoparticles. It is expected as the particle size of chitosan 
nanoparticle is smaller, their surface area will be more and the drug 
release is faster [24]. 
Release kinetics  
It was found that the in vitro drug release of RF4 was best explained 
by Zero-order, as the plots showed the highest linearity (R2 = 
0.982), followed by Higuchi’s equation (R2 = 0.981), and First-order 
(R2 = 0.843). The corresponding plot (log % cumulative drug release 
vs. log time) for the Korsmeyer-Peppas equation (R2 = 0.960) 
indicated good linearity. The release exponent ‘n’ was found to be 
0.631 [27]. Upon fitting the in vitro release data into different 
equations, the optimized formulation showed Zero-order release as 
it has high linearity, followed by Higuchi’s equation and First-order 
as shown in table 5. The value of release component ‘n’ obtained 
using the Korsmeyer-Peppas equation is 0.621 which appears to 
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indicate the anomalous, non-Fickian diffusion suggesting that the 
drug release is controlled by more than one process i.e. 
superposition of both phenomena, the diffusion-controlled and 
swelling-controlled release [25]. 
 
 
Fig. 6: Comparative in vitro drug release profile of RF1 to RF9 
 
 
Fig. 7: Comparative in vitro drug release profile of rosuvastatin calcium-chitosan NPs tablet and pure drug tablet 
 
Full factorial design  
The effect of independent variables chitosan and STPP was analyzed 
by response surface plots using Minitab software 17. Fig. 8 and 9 
shows responses for particles size (Y1) and % cumulative drug 
release (Y2) by the effects of independent variables. Observed 
coefficient values for the drug-loaded nanoparticles are represented 
in Eq. (5) and Eq. (6) [24].  
Y1=403.6+20.7 X1+42.87 X2+37.03X1X2-36.53X12-11.97 X22 …. (5) 
Y2 =85.20+7.787 X1-5.782 X2-5.518 X1X2 …. (6) 
The effect of the particle size and chitosan was thoroughly proven by 
using full factorial design. From the above-generated surface 
response plots illustrated that as the concentration of chitosan 
increases, the value of the dependent variable, particle size increases 
and as the concentration of sodium tripolyphosphate increases the 
value of the dependent variable, particle size also increases. 
Similarly the response surface plots for % drug release shows 
negative effects of independent variable, chitosan concentration 
increases the % drug release was decreased and as the 
concentration of sodium tripolyphosphate increase the % drug 
release was also decreased. The best was selected based on the 
statistical data supportive evaluation. In the graph, it can be seen 
that the polymer ratio of 1 has correlated with the highest percent 
cumulative drug release and also the lowest particle size. Contour 
plot further strengthens the evidence that indicates the various 
colored regions with percent cumulative drug release [23]. 
 
 
Fig. 8: Response surface plot showing effect of factorial variables on particle size and % cumulative drug release 
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Fig. 9: Contour plot of chitosan and sodium tripolyphosphate cumulative drug release and particle size 
 
Stability studies 
Stability studies results indicate that after the 1, 2 and 3 mo accelerated 
stability studies reveals no morphological changes but particle size 
increased, percentage entrapment efficiency and % cumulative release 
decreased in freeze-dried nanoparticles. Stability studies were carried 
out on the optimized formulation RF4 as per ICH guidelines for 90 d. 
By comparing this data with initial data it was observed that there 
was a slight decrease in the percentage entrapment efficiency and 
increase in particle size due to degradation of polymer and 
aggregation of particles (table 5). There was not much change in the 
cumulative percent drug release. Formulation stored at (5±3 °C) 
showed better stability as compared to the formulation stored at 
30±2 °C/65±5% RH. Thus we may conclude that the drug does not 
undergo degradation on storage. Rosuvastatin calcium-chitosan 
nanoparticles can be successfully prepared by the ionotropic 
technique. In vitro release study showed that chitosan nanoparticles 
showed sustained release of drugs for a prolong period of time [26]. 
 
Table 5: Stability data 
Freeze dried optimized batch (RF4) 
   Final at 5±3 °C Final at 30±2 °C/65±5%RH 
 Initial 30 d 60 d 90 d 30 d 60 d 90 d 
Particle size (nm) 381.9±2.10 384.5±3.81 388.2±9.12 394.3±5.24 393.4±5.21 398.9±0.93 402.7±3.81 
% Entrapment efficiency 98.5±0.30 95.6±0.10 93.6±0.21 89.8±0.43 93.7±0.34 91.4±0.21 84.8±0.52 
% Drug release 88.4±0.15 86.7±0.14 85.5±0.28 81.3±0.30 82.4±0.22 81.7±0.25 79.2±0.31 
*Data expressed as (mean±SD (N=3)) 
 
CONCLUSION 
A total of nine formulations (RF1-RF9) were formulated by varying 
the concentration of chitosan (0.1%, 0.2% and 0.3%) and sodium 
tripolyphosphate (0.1%, 0.15% and 0.20% using ionotropic 
technique and the various parameters were evaluated. The sizes of 
nanoparticles were in nanosize range, spherical and discrete, 
particle size increase with an increase in polymer concentration. 
Entrapment efficiency increased with increasing the polymer 
concentration to a certain level and then decreased. RF4 formulation 
was considered as optimized formulation based on drug release 
higher entrapment efficiency (98.5±0.30 %), drug content and good 
Zeta potential of-45.11 mV. In vitro release study showed initial 
burst effect, and then followed by a very slow drug release. 
Evaluation of the release profiles of pure drugs showed that almost 
all the Rosuvastatin calcium was released immediately during first 4 
h, suggesting that the developed nanoparticles can be used as an 
important platform for sustained drug release up to 10 h which 
would contribute to lower dosing frequency. The oral bioavailability 
of Rosuvastatin calcium–chitosan nanoparticles was improved by 
than that of pure drug. From the stability studies, it can be found 
that 5±30 °C is the ideal temperature for the storage of 
nanoparticles. The concentrations of polymer and crosslinking agent 
are the important factors in the development of rosuvastatin calcium 
nanoparticles. In conclusion, this work confirmed that the modified 
ionic gelation method is offers an interesting potential for the 
delivery of hydrophobic drugs with chitosan nanoparticle. 
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